These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1737730)

  • 1. Effect of cilastatin on the urinary metabolism of FCE 22101 in the rat.
    Battaglia R; Strolin Benedetti M; Fontana E
    J Antimicrob Chemother; 1992 Jan; 29(1):84-6. PubMed ID: 1737730
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
    Norrby SR; Burman LA; Sassella D; Corigli R; Cassinelli G; Franceschi G; Dornbusch K
    J Antimicrob Chemother; 1990 Mar; 25(3):371-83. PubMed ID: 2338416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem.
    Schliamser SE; Broholm KA; Liljedahl AL; Norrby SR
    J Antimicrob Chemother; 1988 Nov; 22(5):687-95. PubMed ID: 3209527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicological profile of FCE 22101 and its orally available ester FCE 22891.
    Brughera M; Scampini G; Ferrari ML; Nava A; Mazué G
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():129-35. PubMed ID: 2732134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs.
    Kim SH; Kwon JW; Kim WB; Lee MG
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2524-7. PubMed ID: 10508037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilastatin-insulin interaction in the rat.
    Tompkins GC; Brunner LJ; Luke DR
    Drug Metab Dispos; 1989; 17(1):54-7. PubMed ID: 2566470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disposition and urinary metabolism of 14C-labelled FCE 22891, a pro-drug of FCE 22101, in animals.
    Battaglia R; Benedetti MS; Frigerio E; Vicario G; Roncucci R
    J Antimicrob Chemother; 1990 Jan; 25(1):133-9. PubMed ID: 2318748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doripenem: excess mortality.
    Prescrire Int; 2012 Sep; 21(130):214. PubMed ID: 23016255
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
    Zilberberg MD; Mody SH; Chen J; Shorr AF
    Surg Infect (Larchmt); 2010 Oct; 11(5):409-17. PubMed ID: 20666580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.
    Biglino A; Bonasso M; Gioannini P
    J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary metabolites of 14C-labelled FCE 22101 in animals.
    Strolin Benedetti M; Battaglia R; Vicario G; Roncucci R
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():173-7. PubMed ID: 2732140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenems.
    Schlossberg D; Pietroski N
    Semin Pediatr Infect Dis; 2002 Jan; 13(1):4. PubMed ID: 12118842
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of imipenem/cilastatin on cyclosporine metabolism and excretion.
    Mraz W; Modic PK; Hammer C
    Transplant Proc; 1992 Oct; 24(5):1704-8. PubMed ID: 1412804
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of cilastatin on renal handling of vancomycin in rats.
    Kusama M; Yamamoto K; Yamada H; Kotaki H; Sato H; Iga T
    J Pharm Sci; 1998 Sep; 87(9):1173-6. PubMed ID: 9724573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation on administration method of carbapenems].
    Mikamo H; Ninomiya M; Tamaya T
    Jpn J Antibiot; 2002 Dec; 55(6):875-81. PubMed ID: 12621741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
    Balfour JA; Bryson HM; Brogden RN
    Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of in vitro inactivation of tobramycin by imipenem/cilastatin.
    Ariano RE; Kassum DA; Meatherall RC; Patrick WD
    Ann Pharmacother; 1992 Sep; 26(9):1075-7. PubMed ID: 1421667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.